Stocks in play: Helix BioPharma Corp

Is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021. During the second half of 2021, the Company initiated efforts to validate Helix; an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, and its lead clinical program with external stakeholders to bring in an outside perspective to the company's strategy and future. Helix BioPharma Corp shares T.HBP are trading unchanged at $0.30.

Read:

• As Crypto Mining Undergoes a Sustainable Renaissance, Newer, Greener Operations Arise

• Oncology Drug Developers Looking at Significant Projected Growth Through 2030

• Plant-Based Meats Continue to Sprout Growing Revenues on Year-Over-Year Basis

• No Apparent Need to Panic Over Omicron as Vaccine Developers Are on the Case

• Plant-Based Meats Market Projected to Hit $162 Billion by 2030, as New Products Launch